Europes drug regulator has recommended approving Bayers Vitrakvi, putting the medicine on track to become the first in Europe to tackle tumours with a specific genetic mutation regardless of where in the body the disease started. The drug is being recommended for adults and children with difficult to treat forms of cancer that are driven by a rare genetic mutation known as NTRK gene fusion, the European Medicines Agency (EMA) said http://bit.ly/2Mi6s5o on Friday. The European Commission has the final word on drug approvals but it generally follows EMAs recommendation within a couple of months. The EMA endorsement marks a boost for the German companys drug development pipeline, which many analysts regard as too thin to make up for an expected decline in revenues from its two pharma bestsellers from about 2024.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!